Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment Policymedical mutual - ohio Global PA Prior Auth Policy …
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Global prior authorization for medical drugs (Global PA)

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Medical Mutual prior authorization requirements for new specialty drugs and drugs with significant safety/abuse concerns for Commercial and Medicare Advantage members, with submission/contact procedures and a drug-specific code list (partial).

    Policy Summary
    Payermedical mutual - ohio
    PolicyGlobal prior authorization for medical drugs (Global PA)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 3, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from Medical Drug Management for listed drugs before inpatient or outpatient administration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All new specialty drugsRequire prior authorization
    Commercial & MAPlans affected
    1/1/2025Medication Sourcing date
    1-800-424-7698Prior auth phone
    severalMedicare Advantage refs

    Coverage Criteria and General Policy

    Global prior authorization

    Covered when prior authorization is obtained as specified for each drug and plan:

    Global PA requirements: Prior authorization must be requested for all new specialty drugs and all new drugs with significant safety, clinical, or potential abuse/diversion concerns; follow the Global PA (New Drug Prior Authorization) policy and the drug-specific criteria listed in the drug table.

    Applies to Commercial and Medicare Advantage unless a line item specifically states otherwise.

    Coverage depends on referenced criteria

    Coverage and authorization references are guided by commercial criteria codes and Medicare LCD/NCD/Article references

    PA/criteria follow-up: Coverage depends on meeting the referenced Commercial Criteria or Medicare Advantage Criteria (for example: IC-0071, IC-0266, 201317-MRx, LCD: L33794, Article: A52527).

    Providers must consult the referenced criteria documents for the specific clinical requirements and documentation to support authorization.

    Referenced commercial/Medicare criteria

    Coverage is governed by referenced commercial and Medicare Advantage criteria codes:

    Referenced criteria codes: Multiple products list Commercial Criteria and Medicare Advantage references (examples: 201827, 201424, 95015, IC-0598, NCD:110.24, LCDs); meeting those referenced codes' requirements is necessary for coverage.

    Full clinical criteria are contained in the referenced IC/LCD/NCD/Article documents.

    Prior Authorization for specific therapies

    Coverage notes and PA requirements (as stated in this excerpt)

    PA required for inpatient and/or outpatient: Certain therapies explicitly require prior authorization for inpatient and outpatient use (examples in list: Q2055 Abecma, Q2042 Kymriah, J3398 Luxturna, J1412 Roctavian, J3399 Zolgensma).

    See each drug line for the PA status and whether inpatient and/or outpatient PA is required.

    Medicare Part B step therapy references

    Step therapy / Medicare Part B references

    Refer to Medicare Part B Step Therapy Policy: Several products reference Medicare Part B Step Therapy Policy 201936; when an entry states 'See Medicare Part B Step Therapy Policy 201936' providers must follow that policy's step therapy rules for Medicare Advantage claims.

    Examples and cross-references appear in multiple drug entries; consult Policy 201936 for step logic.

    Coverage conditioned on referenced criteria identifiers

    Listed medications are associated with commercial and Medicare Advantage criteria identifiers that define coverage requirements.

    General: Coverage for a listed HCPCS/CPT/Q/J code requires meeting the Commercial Criteria and/or Medicare Advantage Criteria identifiers shown for that code (examples: 250101 for nemolizumab, 201827 for pegfilgrastim products, 95015 for somatropin).

    Providers must reference the specific criteria document identified by the criterion code when submitting prior authorization requests.

    Medicare Advantage cross-referenced requirements

    Medicare Advantage entries that reference external step therapy or LCD/Article guidance.

    Medicare Advantage step therapy: When the Medicare Advantage Criteria field refers to 'See Medicare Part B Step Therapy Policy 201936' or to LCD/NCD/Article citations (e.g., NCD:110.24, LCD:L33794, Article:A52527), coverage decisions follow those referenced Medicare policies in addition to the listed commercial criteria.

    Include supporting documentation that demonstrates compliance with the referenced Medicare Advantage/LCD/NCD/Article requirements when submitting PA.

    Drug-code to criteria mapping

    Coverage and criteria are determined by referenced internal criteria documents (IC-#### or year codes) and Medicare LCD/NCD or Part B Step Therapy policy where noted.

    Entry-level mapping: For each listed HCPCS/J/Q/C code, coverage is subject to the Commercial Criteria identifier(s) shown (e.g., IC-0007, IC-0679, 201012-2), any cited Medicare LCD/NCD/Article, and any sourcing/site-of-care rules.

    This section is a mapping; consult the referenced IC/LCD/NCD/Article documents for the full clinical criteria required to support authorization.

    Coverage governance for listed medications

    Coverage and authorization references for listed drugs are governed by their commercial criteria identifiers and, where applicable, Medicare Advantage LCD/step therapy policies.

    PA and sourcing requirements: Providers must follow the listed Commercial Criteria (e.g., IC-0718 for Roctavian) and submit prior authorization when an entry indicates 'Prior Authorization required' or when Medicare Advantage notes specify PA for inpatient/outpatient.

    Examples in the list: J1412 Roctavian and J3402 Ryoncil note inpatient and outpatient PA requirements.

    Medicare Part B Step Therapy: When entries reference Medicare Part B Step Therapy Policy 201936 or LCDs (e.g., L38920, L38268), providers must comply with those step therapy rules for Medicare Advantage claims in addition to commercial criteria.

    Multiple entries include 'See Medicare Part B Step Therapy Policy 201936' or LCD references.

    Coverage distinctions (Part B vs Part D)

    Coverage notes and distinctions present in this segment include:

    Part B vs Part D coverage: Some formulations are self‑administered and noted as 'not covered under Part B; may be covered under Part D' (example: Tremfya SC/guselkumab); providers should determine benefit applicability when requesting authorization.

    Refer to Article A52527 and the drug line-item for Part B vs Part D guidance.

    Avastin prior authorization condition

    Authorization required for specific indications:

    Avastin (bevacizumab products): Prior authorization is required for non‑ophthalmic indications only (Commercial Criteria IC-0014); Medicare Advantage notes mirror this requirement and reference the Medicare Part B Step Therapy policy where applicable.

    See individual bevacizumab line items (e.g., Q5129, Q5160, Q5118) for coding and PA instructions.

    Drug-specific linkage to commercial/MA criteria

    Coverage and authorization linkage by drug

    drug_entry: Each drug entry lists Commercial Criteria code(s), Medicare Advantage criteria or notes (LCD/NCD/Article), site‑of‑care flags, and medication sourcing effective dates where applicable; meeting those references is required for coverage and PA.

    Providers must submit documentation that cites the specific Commercial Criteria identifier (IC-####) or Medicare Advantage reference shown on the drug line when requesting authorization.

    Coverage for medical-administered drugs listed in this document is conditioned on prior authorization. Prior authorization must be obtained as specified for each drug and plan; this requirement applies to Commercial and Medicare Advantage members unless an individual line item states otherwise. Providers should submit clinical documentation and the signed prescription to Medical Drug Management or the specialty pharmacy using the payer’s prior approval process when seeking authorization.

    Bevacizumab (Avastin and biosimilars) entries note that prior authorization is required for non‑ophthalmic indications only. Medicare Advantage references and the document’s therapy/step-policy citations (see Medicare Part B Step Therapy Policy 201936 where indicated) mirror this PA requirement.

    Several products in the list are identified as self‑administered. When an entry is labeled self‑administered the drug is typically subject to benefit (prescription/Part D) coverage rules rather than Medicare Part B. Providers must document route of administration and indicate whether the drug is being billed under the medical benefit or the pharmacy/Part D benefit when requesting authorization.

    Medicare applicability: where a line item references Article A52527 or similar Medicare notes, the entry indicates that the drug is self‑administered and not covered under Medicare Part B; it may be covered under Part D. Providers should follow the Article/LCD guidance cited for Medicare Advantage members when determining Part B versus Part D applicability.

    Effective-date note: certain self‑administered products have specific effective dates in the document. For example, Nemluvio has a new PA effective 3/1/2026 and a Part B exclusion effective 6/14/2026 when the product is listed as self‑administered and not covered under Part B. Check each line item for any effective PA or sourcing dates.

    Examples mapping drugs between Part D and Part B in the document include growth hormones and biologics: J2941 (Norditropin / somatropin) is listed as self‑administered and references Article A52527 (may be covered under Part D, not Part B). Similarly, multiple J3590/C9399 entries for self‑administered biologics reference Article A52527 and note Part D applicability.

    The document explicitly references Article A52527 for self‑administered products in Medicare Advantage entries. Where Article A52527 is cited, the payer indicates the drug is self‑administered and not covered under Part B; it may be covered under Part D. Providers should cite Article A52527 in Medicare Advantage authorization requests when applicable.

    Code-mapping examples demonstrating benefit implications: J2941 (Saizen/Humatrope, somatropin) is listed as self‑administered and subject to benefit coverage with Medicare Advantage reference Article A52527. The document also shows Q9998/Q9996 ustekinumab entries paired with Article A52527 and sourcing notes indicating Part D vs Part B distinctions.

    Tremfya (guselkumab) is documented as a self‑administered product; the SC formulation is noted as not covered under Medicare Part B and may instead be covered under Part D. The line item references Article A52527 to support the Part D/Part B determination.

    Additional self‑administered examples include multiple adalimumab and other biologic listings where Commercial Notes state 'Self‑administered; subject to benefit coverage' and Medicare Advantage Criteria reference Article A52527. These entries indicate the payer treats the listed formulations as pharmacy/Part D benefit candidates rather than Part B medical benefit items.

    Investigational/experimental definition excerpt: services, procedures, therapies, devices or supplies that are not approved by governing bodies or do not demonstrate outcomes comparable or superior to current practice standards (per peer‑reviewed evidence) are considered investigational and are subject to non‑coverage determinations.

    The document is primarily an administrative mapping of codes, criteria identifiers and sourcing/site‑of‑care flags rather than an explicit clinical 'not medically necessary' determination list. No standalone clinical NMN statements are present; clinical NMN decisions would be governed by the referenced Commercial Criteria, LCD/NCD, or Article citations.

    Where a product is identified as self‑administered, the entry routinely states it is not covered under Medicare Part B and may be covered under Part D (Article A52527). This constitutes an administrative exclusion from Part B for self‑administered formulations and indicates benefit‑based non‑coverage under the medical benefit.

    The document includes multiple references to LCDs, NCDs, and Medicare Part B Step Therapy Policy 201936 as governing sources for Medicare Advantage coverage (examples shown alongside specific J‑ and Q‑codes). When an LCD/NCD or the Part B Step Therapy policy is cited, coverage decisions for Medicare Advantage follow those referenced policies.

    Clinical coverage or 'not medically necessary' determinations are not stated directly in this file; instead, NMN outcomes would be governed by the referenced Commercial Criteria or Medicare policies (IC codes, LCD/NCD, Article A52527, and Medicare Part B Step Therapy Policy 201936) which contain the clinical logic.

    The repeated Part B versus Part D references emphasize operational implications: when an entry references Article A52527 or explicitly states 'self‑administered; subject to benefit coverage', the product is treated as a pharmacy/Part D benefit candidate and the provider should confirm benefit routing before submitting a medical claim or PA under Part B.

    This document functions as an administrative listing of codes, sourcing start dates, site‑of‑care flags and references to external criteria; it does not include standalone clinical NMN narratives. Providers must consult the referenced criteria documents (IC‑####), LCDs/NCDs and the Part B Step Therapy policy for clinical decision rules.

    The listing maps each drug to its required prior authorization, site‑of‑care or sourcing flags and to the referenced Commercial Criteria or Medicare Advantage policy. For authorization requests, include the specific Commercial Criteria identifier or Medicare reference (IC‑####, NCD/LCD number or Article A52527) shown with the HCPCS/Q/J code on the line item.

    Coding: HCPCS / CPT / J / Q Codes

    Listed drug HCPCS/Codes (partial list)HCPCS
    Q2055Abecma (idecabtagene vicleucel)
    J9264Abraxane (paclitaxel protein bound)
    Q5145Abrilada (adalimumab-afzb)
    J3262Actemra IV (tocilizumab)
    J3590Actemra SC / multiple J3590 entries (tocilizumab and other SC biologics)
    C9399Miscellaneous biologic codes used for several brand products
    J0801Acthar Gel (corticotropin)
    J0791Adakveo (crizanlizumab-tmca)
    Sample drug code entriesmixed
    J9028listed with sourcing starting 1/1/2025; Medicare Advantage Criteria = IC-0753
    J2277Aphexda; motixafortide; Hematopoetic stem cell mobilizer; Commercial Subject to Site of Care = IC-0729
    J0256Aralast NP; alpha-1-proteinase inhibitor; Sourcing Starting 1/1/2025 = ✓; Medicare Advantage Criteria = IC-0052
    J0881Aranesp; darbepoetin alfa; Medicare Advantage Criteria = NCD: 110.21, LCD: L34356
    J2793Arcalyst; rilonacept; Medicare Advantage Criteria = L34356 CDP 210501
    More drug code entriesmixed
    Q5169Armlupeg; pegfilgrastim-unne; Classification = Colony stimulating factors; Commercial Criteria = 201827; New PA requirement effective 7/1/2026
    J9261Arranon Asceniv; nelarabine; Classification = Oncology; Commercial Criteria = IC-0280
    J1554Asceniv; globulin; Classification = Immune globulin; Commercial Criteria = IC-0071
    J9118Asparlas; calaspargase pegol-mknl; Classification = Oncology; Commercial Criteria = IC-0425, IC-0538-(E); Prior Authorization required
    All coded drug entries in these chunksmixed
    J3590Avlayah; tividenofusp alfa-eknm; Classification = Enzyme replacement therapy; Commercial Criteria = 231205; New PA requirement effective 5/1/26
    J1826Avonex; interferon beta-1a; Commercial Criteria = 201306; self-administered; may be covered under Part D
    Q5121Avsola; infliximab-axxq; Classification = Inflammatory conditions; Commercial Criteria = IC-0104
    J9036Belrapzo; dilute; Classification = Oncology; Commercial Subject to Site of Care = IC-0130, MMO-0487-(E)
    J9033Bendamustine; J9033; Classification = Oncology; Commercial Subject to Site of Care = IC-0130, MMO-0487-(E)
    J0490Benlysta IV; belimumab; Classification = Inflammatory conditions; Commercial Subject to Site of Care = 201107; Sourcing Starting 1/1/2025 = ✓ (A,C,S)
    J1556Bivigam; intravenous immune globulin; Commercial Subject to Site of Care = IC-0071; Sourcing Starting 1/1/2025 = ✓ (A,C,S)
    J9999Avzivi / Blenrep entries shown under J9999/C9399; e.g., Avzivi bevacizumab-tnjn; Commercial Criteria = IC-0014; Avastin products require PA for non-ophthalmic indications
    A9590Azedra; iobenguane I-131; Classification = Oncology 201828_MRx
    J9023Bavencio; avelumab; Classification = Oncology; Commercial Subject to Site of Care = IC-0295, IC-0417-(E)
    1–10 of 16
    1/2
    Listed drug HCPCS/Codes and descriptionsHCPCS
    J9145Darzalex (daratumumab); Oncology; Commercial Subject to Site of Care = IC-0266, IC-0383-(E); Medicare Advantage Criteria = IC-0266; Note references Medicare Part B Step Therapy Policy 201936
    J9144Darzalex Faspro SC (daratumumab; hyaluronidase-fihj); Oncology; Commercial Subject to Site of Care = IC-0535, IC-0585-(E); Medicare Advantage Criteria = IC-0535
    J9011Datroway (datopotamab deruxtecan-dlnk); Oncology; Commercial Subject to Site of Care = IC-0785; Medicare Advantage Criteria = IC-0785
    J9348Danyelza (naxitamab-gqgk); Oncology; Commercial Subject to Site of Care = IC-0581; Medicare Advantage Criteria = IC-0581
    J3490/C9399Dawnzera (donidalorsen); Hereditary angioedema; Commercial Subject to Site of Care = 251202; Sourcing Starting 1/1/2025 = (C)
    J0589Daxxify (daxibotulinumtoxinA-lanm); Botulinum toxins; Commercial Subject to Site of Care = IC-0728; Medicare Advantage Criteria = LCD: L39857
    J3121Delatestryl (testosterone enanthate); Testosterone; Commercial Subject to Site of Care = 201602; Medicare Advantage Criteria = NCD: 230.4
    J1071Depo-Testosterone (testosterone cypionate); Testosterone; Commercial Subject to Site of Care = 201602
    J3590/C9399Dupixent (dupilumab) and multiple other entries under J3590/C9399; Classification varies (Inflammatory conditions, Atopic Dermatitis, etc.); Commercial Subject to Site of Care and Medicare Advantage notes often indicate self-administered and Part D/Part B distinctions
    J7318Durolane (hyaluronan or derivative); Viscosupplementation; Commercial Criteria = 99002; Medicare Advantage Criteria = No prior authorization required LCD: L39857
    1–10 of 36
    1/4
    Immune globulin (selected)HCPCS
    J1551Cutaquig (subcutaneous immune globulin); Immune globulin; Commercial Subject to Site of Care = 201317-MRx; Sourcing Starting 1/1/2025 = (A,C,S); Medicare Advantage Criteria = LCD: L33794
    J1555Cuvitru (subcutaneous immune globulin); Immune globulin; Commercial Subject to Site of Care = 201317-MRx; Sourcing Starting 1/1/2025 = (A,C,S); Medicare Advantage Criteria = LCD: L33794
    Sample HCPCS / J-code group (partial)HCPCS
    Q5130Listed with various brand/generic and criteria (e.g., Fylnetra Gamifant; pegfilgrastim-pbbk emapalumab-lzsg)
    J9210Fylnetra Gamifant; pegfilgrastim-pbbk emapalumab-lzsg
    J1569Gamifant Gammagard; emapalumab-lzsg intravenous immune globulin
    Immune globulin J-codesHCPCS
    J1566Gammagard S/D; intravenous immune globulin
    J1561Gammaked / Gamunex-C; intravenous immune globulin
    J1557Gammaplex; intravenous immune globulin
    Immune globulin J-codesHCPCS
    J1566Gammagard S/D; intravenous immune globulin
    J1561Gammaked / Gamunex-C; intravenous immune globulin
    J1557Gammaplex; intravenous immune globulin
    Mixed codes (colony stimulating, inflammatory, HAE)mixed
    J1447Granix; tbo-filgrastim (colony stimulating factor)
    C9399Hadlima; adalimumab-bwwd (inflammatory conditions)
    J0599Haegarda; c-1 esterase inhibitor (hereditary angioedema)
    Oncology / Hemophilia related J-codesHCPCS
    J1411Hemgenix; etranacogene dezaparvovec-drlb (antihemophilic)
    J7170Hemlibra; emicizumab-kxwh (antihemophilics)
    J9355Herceptin; trastuzumab (oncology)
    Additional oncology / inflammatory codesHCPCS
    J9325Imlygic (T-Vec); talimogene laherparepvec (oncology)
    Q5098Imuldosa IV/SC; ustekinumab-srlf (inflammatory conditions)
    Q5160bevacizumab-nwgd (Avastin biosimilar)
    Sample drug HCPCS/CPT group Amixed
    C9309Listed with J9207; related PA requirements and commercial/Medicare criteria
    J9207Ixempra / onasemnogene abeparvovec-brve ixabepilone (document lists both brand/generic associations)
    J2782Listed alongside J9207 and J9281; multiple classifications including oncology and ophthalmic injections
    J9281Listed with J2782; associated classifications
    Sample drug HCPCS/CPT group Bmixed
    J9272Jemperli (dostarlimab-gxly)
    Q5160bevacizumab-nwgd (Avastin products) - PA for non-ophthalmic indications only
    J3590Jubereq / denosumab-desu and multiple J3590/C9399 paired entries for various drugs
    C9399Used as a catch-all code paired with J3590 for multiple products
    J9354Kadcyla (ado-trastuzumab)
    Sample drug HCPCS/CPT group Cmixed
    Q2042Kymriah (tisagenlecleucel)
    J3398Luxturna (voretigene neparvovec-)
    J3590Repeated use as generic code for multiple newer specialty agents (e.g., Leqembi, Lerochol)
    Listed HCPCS (examples starting with N)HCPCS
    J3590Nemluvio / nemolizumab-ilto; Classification = Inflammatory conditions; Commercial Criteria = 250101
    C9399Nemluvio / nemolizumab-ilto (alternate) ; Commercial Criteria = 250101
    Colony stimulating factorsHCPCSCovered
    J2506Neulasta / pegfilgrastim; Colony stimulating factors; Commercial Criteria = 201827
    J1442Neupogen / filgrastim; Colony stimulating factors; Commercial Criteria = 201424
    Q5110Nivestym / filgrastim-aafi; Colony stimulating factors; Commercial Criteria = 201424
    Q5148Nypozi / filgrastim-txid; Colony stimulating factors; Commercial Criteria = 201424
    Q5122Nyvepria / pegfilgrastim-apgf; Colony stimulating factors; Commercial Criteria = 201827
    Growth hormone & inflammatory biologicsHCPCS
    J2941Norditropin / somatropin; Growth hormone; Commercial Criteria = 95015
    J2267Omvoh (IV/SC) / mirikizumab-mrkz; Inflammatory conditions; Commercial Criteria = 231202/231203
    J0129Orencia IV/SC / abatacept; Inflammatory conditions; Commercial Criteria = 200809 / 201725
    Oncology agentsHCPCSCovered
    J9205Onivyde / irinotecan liposome; Oncology; Commercial Criteria = IC-0256, IC-0428-(E)
    J9264Paclitaxel Albumin-Bound / paclitaxel albumin-bound particles; Oncology; Commercial Criteria = IC-0001, IC-0360-(E)
    J9177Padcev / enfortumab vedotin-ejfv; Oncology; Commercial Criteria = IC-0521, IC-0542-(E)
    J9304Pemfexy / pemetrexed; Oncology; Commercial Criteria = IC-0007, MMO-0489-(E)
    Hematology / rare disease therapiesHCPCSCovered
    J1576Panzyga / intravenous immune globulin; Hematology; Commercial Criteria = IC-0071
    J1640Panhematin / hemin; Hematology; Commercial Criteria = 211001
    J3404Papzimeos / zopapogene imadenovec- drba; Rare disease; Commercial Criteria = IC-0807
    Oncology J-codes (examples)HCPCS
    J9304Pemfexy pemetrexed
    J9306Perjeta pertuzumab
    J9316Phesgo pertuzumab; trastuzumab; hyaluronidase
    Oncology / Radiotherapeutic agentsHCPCS
    A9607Pluvicto lutetium (177LU) vipivotide tetraxetan
    J9309Polivy polatuzumab vedotin- piiq
    Immune globulin / ESA / Alpha-1HCPCS
    J1459Privigen intravenous immune globulin
    J0885Procrit epoetin alfa
    J0256Prolastin-C alpha-1-proteinase inhibitor
    Q-codes (immune / oncology)HCPCS
    Q2043Provenge sipuleucel-t
    Q9997Pyzchiva IV / Ustekinumab-ttwe (branded/unbranded)
    Q9996Pyzchiva SC / ustekinumab-ttwe
    Various combined J/C codesHCPCS
    J3590unclassified J-code entries (used with C9399 in matrix)
    C9399Unclassified drug code (used in combination entries)
    J1745infliximab unbranded
    Gene therapy / growth factor / oncologyHCPCS
    J1412Roctavian valoctocogene roxaparvovec-rvox
    J1449Rolvedon eflapegrastim-xnst
    J9318Romidepsin (liquid)
    Listed J-codes (partial)HCPCS
    J9311Referenced: J9311, Sourcing Starting 1/1/2025
    J3490Rivfloza; hyaluronidase human nedosiran; classified as Rare disease (also C9399)
    Additional J-codesHCPCS
    J1412Roctavian; valoctocogene roxaparvovec-rvox; Antihemophilics
    J1449Rolvedon; eflapegrastim-xnst; Colony stimulating factors
    J9318Romidepsin; romidepsin non-lyophilized; Oncology
    J0596Ruconest; c1 esterase inhibitor [recombinant]; Hereditary angioedema
    Oncology biologicsHCPCS
    Q5119Ruxience; rituximab-pvvr; Oncology
    J9061Rybrevant; amivantamab-vmjw; Oncology
    J9021Rylaze; asparaginase erwinia chrysanthemi; Oncology
    Hormones and rare disease therapiesHCPCS
    J2941Saizen; somatropin; Growth hormone
    J1299Soliris; eculizumab; Rare disease
    J1930Somatuline Depot; lanreotide; Oncology, Endocrine
    Ophthalmic / viscosupplementationHCPCS
    J7321Intra-articular injection, per dose; Viscosupplementation
    J2779Susvimo Syfovre; ranibizumab pegcetacoplan; Ophthalmic injections
    Cellular therapiesHCPCS
    J3055Talvey; talquetamab-tgvs; Oncology
    Q2053Tecartus; brexucabtagene; Oncology (CAR-T)
    Q2057Tecelra; autoleucel Afamitresgene; Oncology (cell therapy)
    Listed HCPCS/CPT codes in this segmentHCPCS
    J9380Tecvayli (teclistamab-cqyv) — Oncology
    J3490Unspecified code used with multiple brand/generic listings (e.g.,Tecvayli, Tryngolza, Tyvaso DPI, others)
    C9399Unspecified/Other Part B - used with several rare disease / specialty entries
    Selected drug HCPCS entriesHCPCS
    J3241Tepezza / teprotumumab-trbw — Rare disease
    J1628Tremfya IV/SC / guselkumab — Inflammatory conditions
    J2323Tysabri / natalizumab — Multiple Sclerosis
    Oncology drug codesHCPCS
    J9303Vectibix / panitumumab — Oncology
    Q5129Vegzelma / bevacizumab-adcd — Oncology (Avastin products)
    Hematology drug codesHCPCS
    J9332Vyvgart / efgartigimod alfa — Hematology: MG
    J9334Vyvgart Hytrulo / efgartigimod alfa hyaluronidase-qvfc — Hematology: MG
    Listed HCPCS/Q/J codes (sample beginning of section)mixed
    J3490Wainua eplontersen (C9399 referenced)
    C9399Wainua eplontersen (alternate code reference)
    Q5138Wezlana IV (ustekinumab-auub)
    All HCPCS/Q/J codes listed in these chunksmixed
    Q5137Wezlana SC (ustekinumab-auub)
    J3590General J3590 entries (e.g., Winrevair sotatercept; Xtrenbo denosumab-qbde; Yartemlea narsoplimab-wuug)
    Q5136Wyost (denosumab-bbdz)
    Q5159Xbryk (denosumab-dssb)
    J1558Xembify (subcutaneous immune globulin)
    J0218Olipudase alfa / incobotulinumtoxinA listing
    J9228Yervoy (ipilimumab)
    Q2041Yescarta (axicabtagene ciloleucel)
    Q5100Yesintek IV (ustekinumab-kfce)
    Q5101Zarxio (filgrastim-sndz)
    1–10 of 25
    1/3
    Medication Sourcing Start Date
    Medication Sourcing Start Date1/1/2025
    Affected itemsDrugs flagged with 'Sourcing Starting 1/1/2025' in the drug table (multiple J/Q codes such as J1551, J1555, J1569, J9309, etc.)
    Sourcing typesFlags shown as (A,C,S) adjacent to entries indicating sourcing categories applicable starting 1/1/2025

    Provider Actions, Submission & Prior Authorization

    Prior Authorization

    Prior authorization required

    Request prior authorization for listed specialty drugs before inpatient or outpatient administration; prior authorization applies to Commercial and Medicare Advantage members unless a specific entry states otherwise. Failure to obtain required PA may result in denial of coverage for outpatient drug administration.

    • PA requirement applies to all new specialty drugs and new drugs with significant safety/abuse concerns.
    • For Medicare Advantage, Medical Mutual follows CMS guidance; include Medicare-specific criteria or LCD/NCD references when applicable.
    Prior Authorization

    Prior Authorization required for J9118 (Asparlas)

    Asparlas (J9118) requires prior authorization per the commercial criteria listed for this agent.

    • Commercial Criteria: IC-0425, IC-0538-(E).
    Note

    No PA required (commercial) for Q5158

    No prior authorization is required under the commercial criteria for Bomyntra/denosumab-bnht (Q5158); note Medicare Advantage references may differ.

    • Commercial Criteria: No PA required.
    • Medicare Advantage: see Part B Step Therapy Policy 201936; PA may be required except when used for osteoporosis treatment/prevention.
    Prior Authorization

    Breyanzi PA requirement (Q2054)

    Breyanzi (Q2054) requires prior authorization for both inpatient and outpatient administration; submit PA referencing the listed commercial and Medicare criteria.

    • Commercial Criteria: IC-0590, IC-0617-(E).
    • Medicare Advantage Criteria: NCD: 110.24 — PA required for inpatient and outpatient.
    Prior Authorization

    Casgevy PA requirement (J3392)

    Casgevy (J3392) requires prior authorization for inpatient and outpatient use; include the referenced commercial criteria when submitting.

    • Commercial Criteria: IC-0744.
    • Commercial Subject to Site of Care and Sourcing flags are noted in the entry.
    Prior Authorization

    Prior Authorization required for J1323 and J9321

    Prior authorization is required for Elrexfio (J1323) and Epkinly (J9321) for inpatient and outpatient administration; include the listed commercial criteria in the submission.

    • J1323 Commercial Criteria: IC-0724, IC-0758-(E).
    • J9321 Commercial Criteria: IC-0710, IC-0747-(E).
    Prior Authorization

    Medicare Advantage / LCD-related prior authorization

    Some J3590/C9399-coded self‑administered drugs and immune globulin products reference Medicare Advantage criteria and LCDs; providers must follow the referenced Medicare Advantage/LCD guidance when obtaining PA or submitting documentation.

    • Examples: immune globulin entries reference LCDs (e.g., L33794, L38268) and Therapy Policy 201936.
    • Include Medicare Advantage criteria identifiers in PA requests when applicable.
    Prior Authorization

    New PA requirement example (J7322 Hymovis One) effective 4/1/26

    Hymovis One (J7322) has a new prior authorization requirement effective 4/1/2026; verify PA applicability and submit authorization accordingly for Commercial and Medicare Advantage members.

    • Commercial Criteria: 99002 (viscosupplementation).
    • Medicare Advantage notes reference Part B Step Therapy Policy 201936.
    Step Therapy

    Therapy Policy / Medicare Part B Step references

    Several entries reference the Medicare Part B Step Therapy Policy 201936; when a drug line references that policy, follow its step therapy rules and include step therapy documentation with the PA for Medicare Advantage members.

    • Examples referencing Policy 201936 include bevacizumab, daratumumab, pegfilgrastim/filgrastim products and many oncology agents.
    • Medicare Advantage entries may note new step therapy requirements with effective dates — follow those dates.
    Prior Authorization

    PA requirement and effective dates

    Multiple drugs have PA requirements with specific effective dates; providers must check each line item for the PA effective date and submit PA for dates on or after the listed effective date.

    • Examples: new PA requirements effective 1/1/2026, 3/1/26, 4/1/26, 7/1/26 are noted in various entries.
    • Include the referenced Commercial or Medicare criteria code when submitting PA.
    Prior Authorization

    Nemluvio (J3590, C9399) PA (new effective 3/1/26)

    Nemluvio (nemolizumab-ilto) reported under J3590/C9399 requires a new prior authorization effective 3/1/2026; note that effective 6/14/2026 the product is noted as self‑administered and may not be covered under Medicare Part B.

    • Commercial Criteria: 250101.
    • Medicare Advantage notes: New PA effective 3/1/26; effective 6/14/26 drug is self‑administered and not covered under Part B (may be Part D).
    Documentation Required

    Norditropin (J2941) PA/coverage and documentation notes

    Norditropin / somatropin (J2941) is listed as self‑administered and subject to benefit coverage; include documentation of route and benefit applicability and reference Commercial Criteria 95015 or Medicare Article A52527 when submitting PA or coverage inquiries.

    • Commercial Criteria: 95015.
    • Medicare Advantage: Article A52527 — drug is self‑administered and not covered under Part B; may be covered under Part D.
    Prior Authorization

    Oncology/inflammatory agents PA references

    Multiple oncology and inflammatory agents reference commercial criteria and Medicare Advantage criteria and may require prior authorization consistent with those references; providers must submit PA citing the listed criteria.

    • Include the Commercial Criteria (IC-####) or Medicare LCD/NCD citation when submitting PA.
    • Examples include pemetrexed (J9304), padcev (J9177), and other oncology biologics.
    Prior Authorization

    Roctavian prior authorization (J1412)

    Roctavian (J1412) requires prior authorization for both inpatient and outpatient administration; include the Commercial Criteria IC-0718 in the request.

    • Commercial Criteria: IC-0718.
    • Submit documentation supporting inpatient or outpatient use per the listed criteria.
    Documentation Required

    Rituximab / related PA references

    Rituximab products (e.g., J9312, Q5123, J9311) reference Medicare LCDs and the Medicare Part B Step Therapy Policy 201936; include the LCD/IC references and step therapy documentation when requesting authorization.

    • Medicare Advantage Criteria: LCD: L38920, LCD: L38268 (varies by product).
    • PA requests should reference the applicable LCD/IC code and Part B Step Therapy Policy 201936 when noted.
    Prior Authorization

    Prior Authorization required for specified drugs (examples)

    Certain high‑cost therapies and specified drugs require prior authorization for inpatient and outpatient administration; providers must submit PA referencing the listed Commercial and Medicare Advantage criteria for each drug.

    • Examples: Q2053 (Tecartus), Q2057 (Tecelra), J1412 (Roctavian), J3402 (Remestemcel-L).
    • Follow the listed IC/NCD/LCD references in the drug entry when submitting PA.
    Prior Authorization

    Prior Authorization / New PA effective dates (examples)

    Multiple listed drugs have new prior authorization effective dates (for example olezarsen effective 1/1/2026 and other agents with 2026 effective dates); verify the effective date in the drug entry and obtain PA on or after that date.

    • Examples: entries note new PA or sourcing effective dates of 1/1/2026, 2/1/26, 3/1/26, 4/1/26, 5/1/26, 7/1/26.
    • Ensure PA submission cites the effective date and applicable criteria.
    Documentation Required

    Drugs subject to commercial criteria and site-of-care sourcing

    Some drugs (e.g., Tysabri J2323, Ultomiris J1303) reference commercial criteria and site‑of‑care or medication sourcing requirements; when site‑of‑care or sourcing flags are present include those program requirements in the authorization submission.

    • Check Medication Sourcing Program effective 1/1/2025 and any later sourcing effective dates.
    • Include site‑of‑care IC identifiers when arranging administration.
    Prior Authorization

    Prior Authorization required for high-cost therapies and gene therapies

    Prior authorization is required for several high-cost therapies and gene/cell therapies (examples include Q2041 Yescarta; J3399 Zolgensma; J3389 Zevaskyn); obtain PA for inpatient and outpatient use where indicated.

    • Q2041 (Yescarta): PA required for inpatient and outpatient.
    • J3399 (Zolgensma) and J3389 (Zevaskyn): PA required for inpatient and outpatient.
    Step Therapy

    Step therapy references (general)

    Step therapy requirements from the Medicare Part B Step Therapy Program may apply to certain drugs; when a line item references Part B Step Therapy Policy 201936 include documentation demonstrating compliance with that policy for Medicare Advantage members.

    • Many ophthalmic, oncology, colony stimulating factor and immune globulin entries reference Policy 201936.
    • Follow the referenced policy for step sequencing and prior therapy requirements.
    Step Therapy

    Medicare Part B Step Therapy references (examples)

    Medicare Part B Step Therapy Policy 201936 is cited for multiple agents (examples: Avtozma, Avgemsi, bevacizumab products); providers must follow that policy for Medicare Advantage PA submissions and include step therapy documentation where required.

    • Entries that state 'See Medicare Part B Step Therapy Policy 201936' require compliance with that policy.
    • New Medicare Advantage step therapy requirements and effective dates (e.g., 5/1/2026) are noted in several entries.
    Step Therapy

    Medicare Part B Step Therapy references (multiple entries)

    Multiple entries reference Medicare Part B Step Therapy Policy 201936 or list Medicare Advantage step therapy changes effective in 2026; when applicable, follow that policy and include related documentation with the PA request.

    • Examples include daratumumab (J9145/J9144) and selected pegfilgrastim products.
    • Note new MA step therapy effective dates (e.g., 5/1/2026) where listed.
    Step Therapy

    Refer to Part B Step Therapy Policy

    See the Medicare Part B Step Therapy Policy 201936 for products that explicitly reference it (for example bevacizumab and other oncology agents); include the step therapy policy citation in the PA submission for Medicare Advantage members.

    • Examples: bevacizumab (Avastin products) reference IC-0014 and Policy 201936.
    • Providers must consult the referenced policy for step logic.
    Step Therapy

    Medicare Part B Step Therapy cross-reference

    Medicare Advantage entries frequently state 'See Medicare Part B Step Therapy Policy 201936' — when present, providers must comply with that policy and supply step therapy documentation with prior authorization requests.

    • Applicable to multiple oncology, ophthalmic and biologic agents.
    • Check for MA-specific effective dates noted in individual entries.
    Documentation Required

    Submission requirements

    When submitting prior authorization requests, include clinical notes, a signed prescription, and member demographics; follow the Medical Drug Management contact methods (phone, fax, web) or the specialty pharmacy referral instructions.

    • Medical Drug Management phone: 1-800-424-7698; fax: 1-888-656-1948; web: www.gatewaypa.com.
    • Specialty pharmacy submissions should indicate medical benefit billing, sourcing/white-bag instructions, ship-to location and required delivery date to avoid delays.
    Documentation Required

    Avonex coverage note (J1826, Q3027)

    Avonex (J1826, Q3027) is noted as self‑administered and subject to benefit coverage; for Medicare Advantage, the entry references Article A52527 and indicates the drug is not covered under Part B and may be covered under Part D.

    • Commercial Criteria: 201306.
    • Document route of administration and benefit applicability on the PA submission.
    Documentation Required

    Supporting documentation for referenced criteria

    Include the cited Commercial Criteria or Medicare Advantage Criteria identifiers (IC-####, LCD/NCD, Article) in the PA submission as supporting references; PA decisions depend on meeting those referenced criteria.

    • Examples: IC-0071, IC-0266, LCD: L33794, Article: A52527, Medicare Part B Step Therapy Policy 201936.
    • Cite the exact criteria identifier shown in the drug line item when submitting documentation.
    Documentation Required

    Self-administered drug documentation (Norditropin example)

    Norditropin (J2941) and other self‑administered products should have documentation that reflects route of administration and whether the drug is a pharmacy/Part D benefit or a medical/Part B benefit; include Article A52527 references for Medicare Advantage submissions.

    • Commercial Criteria for J2941: 95015.
    • Medicare Advantage: Article A52527 — self‑administered drugs may not be covered under Part B.
    Step Therapy

    Medicare Part B Step Therapy references (submission guidance)

    When a drug entry references Medicare Part B Step Therapy Policy 201936, include relevant step therapy documentation with PA submissions for Medicare Advantage members and follow any MA-specific step therapy effective dates.

    • Many oncology and biologic agents reference Policy 201936 — providers must follow that policy's step sequencing and documentation requirements.
    • Note MA-specific effective dates (e.g., 5/1/2026) listed in entries.
    Denial Risk

    Avastin coverage note and PA condition

    Avastin/bevacizumab products require prior authorization for non‑ophthalmic indications only; failure to obtain PA for non‑ophthalmic use may result in denial.

    • Commercial Criteria: IC-0014 (Avastin non‑ophthalmic PA requirement).
    • Medicare Advantage entries reference Part B Step Therapy Policy 201936.
    Prior Authorization

    Blenrep PA requirement (effective 11/7/25)

    Blenrep (listed under J9999/C9399) has a new prior authorization requirement effective 11/7/2025; obtain PA per the listed commercial criteria and include the ICD/criteria references.

    • Commercial Subject to Site of Care: IC-0561.
    • New PA requirement effective 11/7/25 as noted in the entry.
    Prior Authorization

    Asparlas PA requirement (J9118)

    Asparlas (J9118) is identified as requiring prior authorization; include the commercial criteria cited for the drug when submitting PA.

    • Commercial Criteria: IC-0425, IC-0538-(E).
    Denial Risk

    Prior Authorization required (Elrexfio J1323, Epkinly J9321)

    Elrexfio (J1323) and Epkinly (J9321) require prior authorization for inpatient and outpatient use; failure to obtain PA may result in claim denial.

    • Include commercial criteria IC-0724 for J1323 and IC-0710 for J9321 in PA requests.
    • Medicare Advantage notes mirror the PA requirement.
    Denial Risk

    LCD/Step Therapy denial risk for immune globulin products

    Some immune globulin products (e.g., J1569, various Gammagard entries) are subject to Medicare LCDs and Part B step therapy references; failing to meet LCD/step therapy requirements may trigger coverage limitations or denials.

    • Medicare Advantage Criteria include multiple LCDs (L38268, L35891, L33610) and Therapy Policy 201936.
    • Commercial Criteria: IC-0071 for many IVIG products — include IC reference in PA.
    Denial Risk

    Avastin PA requirement (non-ophthalmic) — denial risk

    Avastin (bevacizumab products) require prior authorization for non‑ophthalmic indications only; absence of PA for non‑ophthalmic administration may result in denial.

    • Commercial Criteria: IC-0014.
    • Medicare Advantage references Part B Step Therapy Policy 201936 for related rules.
    Denial Risk

    Prior Authorization required — failure to obtain may lead to denial

    Prior authorization is required for multiple listed drugs; providers should obtain PA before administration to avoid denials.

    • This global PA requirement applies to Commercial and Medicare Advantage unless specifically exempted in a line item.
    • Failure to obtain PA may lead to denial of coverage for outpatient administrations.
    Denial Risk

    Nemluvio PA requirement (denial risk if not obtained)

    Nemluvio (nemolizumab-ilto) has a new PA requirement effective 3/1/2026; obtain PA for dates on or after that effective date to avoid denial. The entry also notes that effective 6/14/2026 the drug is self‑administered and may not be covered under Part B.

    • Commercial Criteria: 250101.
    • Medicare Advantage: note MA PA effective date and Part B/Part D distinction on 6/14/26.
    Denial Risk

    Q5168 and related PA (effective 7/1/2026) — denial risk

    New PA requirements effective 7/1/2026 apply to certain ophthalmic agents (for example Q5168); providers must obtain PA on or after the effective date to avoid denial.

    • Q5168 (ranibizumab-leyk) lists a new PA requirement effective 7/1/2026.
    • Check the drug line for the exact effective date and PA instructions.
    Denial Risk

    Prior Authorization required for Roctavian (denial risk)

    Roctavian (J1412) requires prior authorization for inpatient and outpatient administration; lack of PA may result in denial.

    • Commercial Criteria: IC-0718 — include this identifier in PA submissions.
    • Medicare Advantage notes also require PA for inpatient and outpatient.
    Prior Authorization

    Prior Authorization / PA notes (Rivfloza example)

    Rivfloza and other listed products using J3490/C9399 codes have prior authorization noted in their line items; include the referenced Commercial Criteria when submitting PA.

    • Example: Rivfloza (J3490/C9399) Commercial Criteria = 240101; Medicare Advantage indicates PA required.
    • Use the exact code pairing and criteria identifier shown in the drug entry.
    Prior Authorization

    Prior Authorization for cellular therapies (CAR‑T and cell therapies)

    Prior authorization is required for multiple listed drugs including certain CAR‑T and cell therapies (e.g., Q2053 Tecartus, Q2057 Tecelra); obtain PA for inpatient and outpatient use where stated.

    • Q2053/Q2057 entries explicitly state PA required for inpatient and outpatient.
    • Include NCD: 110.24 or IC references as applicable for Medicare Advantage.
    Prior Authorization

    PA required for Tecvayli (teclistamab-cqyv)

    Tecvayli (teclistamab-cqyv) (J9380) requires prior authorization for both inpatient and outpatient use; include the commercial criteria identifiers (IC-0682, IC-0706-(E)) in PA requests.

    • Commercial Criteria: IC-0682, IC-0706-(E).
    • Medicare Advantage: PA required for inpatient and outpatient per the entry.
    Prior Authorization

    Prior Authorization required for Q2041 (Yescarta)

    Yescarta (Q2041) requires prior authorization for inpatient and outpatient use; include the listed commercial criteria and any Medicare NCD references when submitting PA.

    • Q2041 Commercial Subject to Site of Care: 201733; include IC/NCD references in documentation.
    • Medicare Advantage notes reference NCD: 110.24.
    Prior Authorization

    Prior Authorization required for gene therapies (J3389, J3399)

    Prior authorization is required for certain gene therapies (J3389, J3399) for inpatient and outpatient administration; submit PA with the applicable commercial criteria identifier (e.g., IC-0796) to avoid denial.

    • J3389 (Zevaskyn) Commercial Criteria: IC-0796 — PA required for inpatient and outpatient.
    • J3399 (Zolgensma) Commercial Criteria: 201901 — PA required for inpatient and outpatient.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Site-of-Care and Medication Sourcing

    Billing Rule

    Provide site-of-care and sourcing details when entries flag Medication Sourcing or Site-of-Care

    Some PA requirements are tied to site-of-care or Medication Sourcing Program flags (Medication Sourcing starting 1/1/2025); when a drug is flagged as Commercial Subject to Site of Care or Sourcing Starting 1/1/2025, include site and sourcing details in the PA and follow the Medication Sourcing Program guidance.

    • Specify 'drug to be billed under the medical benefit' and whether the drug is to be sourced/white‑bagged and the ship‑to location on referral forms.
    Billing Rule

    Follow the specified site‑of‑care designation in the drug entry

    When a drug line is marked 'Commercial Subject to Site of Care' providers must follow the listed site-of-care policy (examples: infusion center, office, home) for arranging administration and include that site information in the PA submission.

    • Check the specific drug row for the site-of-care designation (e.g., 201317-MRx) and follow the referenced IC/site policy.
    Documentation Required

    Include home‑administration/site notes for subcutaneous immune globulins

    For subcutaneous immune globulins (e.g., J1551 Cutaquig, J1555 Cuvitru) which are marked 'Commercial Subject to Site of Care = 201317-MRx ✓' include the site-of-care designation and sourcing flags in the submission since home administration or pharmacy benefit applicability may affect coverage.

    Billing Rule

    Confirm and document permitted administration location when site‑of‑care flag is present

    Many infusion and specialty products are flagged Commercial Subject to Site of Care (examples annotated across the list); when present, providers should confirm permitted administration locations (infusion center, outpatient hospital, office, home) and note that location on the PA.

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Commercial Subject to Medication Sourcing Starting 1/1/2025 (definition/flag)
    DefinitionIndicates the payer will apply a medication sourcing requirement beginning January 1, 2025 for the listed drug.
    Example entriesSubcutaneous immune globulins (J1551, J1555) show 'Sourcing Starting 1/1/2025 = ✓ (A,C,S)'.
    Provider implicationSourcing requirement may dictate procurement pathway or preferred source when submitting prior authorization starting 1/1/2025.
    Commercial Subject to Site of Care (definition/flag)
    DefinitionFlag that the drug is subject to site-of-care controls or specific site-of-care policy codes (e.g., 201317-MRx, IC-0581).
    Example entriesJ1551 and J1555 marked 'Commercial Subject to Site of Care = 201317-MRx ✓' (subcutaneous immune globulins).
    Action for providersConfirm permitted administration setting (infusion center, office, home) per the referenced site-of-care criteria when requesting PA.
    Commercial Subject to Site of Care / Medication Sourcing (flag examples)
    Flag combinationIndicates the drug is subject to both site-of-care restrictions and medication sourcing (e.g., 'Commercial Subject to Site of Care = ✓' plus 'Sourcing Starting 1/1/2025 = ✓').
    ExampleEntries like J1551/J1555 show both 'Commercial Subject to Site of Care = 201317-MRx ✓' and 'Sourcing Starting 1/1/2025 = ✓ (A,C,S)'.
    Provider stepWhen both flags apply, include site-of-care and sourcing documentation with the PA submission per listed Commercial Criteria code.
    Commercial Subject to Medication Sourcing Starting 1/1/2025 (flag)
    Operational flagMarks drugs that will be subject to medication sourcing beginning January 1, 2025 (triggers sourcing workflows).
    Noted change datesSome entries also reference later sourcing updates (e.g., new medication sourcing requirements effective 4/1/26 or 7/1/26) alongside the 1/1/2025 start flag.
    ExampleJ1569 (Gammagard Liquid ERC) shows 'Commercial Subject to Medication Sourcing Starting 1/1/2025 = ✓ (A,C)'.
    Classification (therapeutic class labels adjacent to entries)
    Classification labelTherapeutic classification (e.g., Oncology, Rare disease, Immune globulin) is shown adjacent to each drug/code entry.
    PurposeHelps identify applicable criteria sets and site-of-care/sourcing rules for each therapeutic area.
    ExampleJ9309 (Polivy) is classified as Oncology and annotated with sourcing/site flags and IC criteria.
    Sourcing Starting (dates such as 1/1/2025 or other effective sourcing dates)
    Sourcing start date meaning'Sourcing Starting' indicates the effective date when the payer's sourcing or procurement requirement applies (commonly 1/1/2025).
    Other effective datesSome entries list alternate effective dates for new sourcing requirements (examples: 4/1/26, 7/1/26) in addition to 1/1/2025.
    Provider implicationVerify the sourcing start date shown on the drug line when preparing procurement/authorization plans.
    Sourcing Starting (operational flag example)
    Operational exampleEntry shows 'Commercial Subject = ✓ (A)' indicating operational sourcing applied starting 1/1/2025 for that code.
    Example codesC9309 / J9207 entries indicate 'Sourcing Starting 1/1/2025 Commercial Subject = ✓ (A)' and note new PA effective dates.
    ActionImplement sourcing workflow for flagged items on or after the stated sourcing start date.
    Commercial Criteria / Medicare Advantage Criteria (IC numbers, LCD refs)
    Commercial Criteria identifiersInternal commercial criteria codes (e.g., IC-0718, 201827) referenced next to drug entries drive coverage decision rules.
    Medicare Advantage referencesMedicare Advantage entries reference LCD/NCD or therapy policies (e.g., LCDs, 'See Medicare Part B Step Therapy Policy 201936').
    UsageProviders must cite the listed IC/LCD/NCD identifiers when submitting authorization documentation.
    Self-administered (definition/example Tremfya)
    DefinitionSelf-administered: drug administered by the patient; may be subject to pharmacy benefit (Part D) rather than Medicare Part B.
    ExampleTremfya (J1628/J1628 entries) noted as self‑administered and 'not covered under Part B; may be covered under Part D'.
    Provider noteWhen an entry is self‑administered, confirm benefit applicability (Part B vs Part D) before submitting PA under medical benefit.
    Medication sourcing (operational flag definition)
    DefinitionMedication sourcing: an operational flag indicating a new sourcing requirement for the drug starting on a specified effective date.
    ExamplesEntries show 'Sourcing Starting 1/1/2025' or 'New medication sourcing requirement effective 4/1/26/7/1/26' as sourcing notes.
    ImplicationTriggers procurement and preferred-source workflows that affect prior authorization processing and billing.
    Commercial Subject to Site of Care (definition/flag)
    DefinitionCommercial Subject to Site of Care: designation that a drug is subject to site-of-care commercial criteria (e.g., infusion center vs home) with an associated policy code.
    ExamplesJ9023 (Bavencio) and many immune globulin/biologic entries list specific site-of-care codes (e.g., IC-0295, 201317-MRx) and a ✓ flag.
    Provider actionFollow the referenced site-of-care commercial criteria when scheduling administration and submitting PA.

    Initial Therapy References & Criteria Identifiers

    Initial therapy references (drug-specific IC numbers / Medicare articles)

    Drug-specific criteria references are listed in the drug table (IC numbers or Medicare articles/LCDs).

    Drug-specific criteria: Each drug references a Commercial Criteria code (e.g., IC-0598) or Medicare Advantage reference (e.g., NCD:110.24, LCD:L33794, Article:A52527) that defines initial coverage requirements; see the individual drug entry for the exact criteria identifier to cite on the PA request.

    This initial therapy reference list points to external criteria documents for full clinical detail.

    Initial therapy references (continued)

    Drug-specific criteria references are listed in the drug table (IC numbers or Medicare articles/LCDs). (continued)

    Drug-specific criteria (continued): Examples in the drug table include Commercial Criteria like IC-0071 for immune globulins, 201827 for colony stimulating factors, 95015 for growth hormone (somatropin), and Medicare references such as Article A52527 indicating self‑administered products may be Part D.

    Providers should cite the exact IC/LCD/NCD/Article identifier from the drug line when submitting PA.

    Step Therapy and Part B Step Program

    ReferenceSummary / Instruction
    Medicare Part B Step Therapy Program (general)Medicare Part B Step Therapy Program may apply to certain drugs; providers must follow the referenced Part B step therapy policies where indicated in individual drug entries.
    See Medicare Part B Step Therapy Policy 201936Multiple drug entries reference Policy 201936 — follow that policy for step therapy sequencing and requirements for Medicare Advantage and Part B claims where noted.
    ReferenceSummary / Instruction
    Policy 201936 (explicit reference)Numerous oncology and biologic agents list 'See Medicare Part B Step Therapy Policy 201936' — include the Part B Step Therapy requirements when submitting authorizations for Medicare Advantage members.
    Examples citing 201936 (daratumumab, pemfexy, others)Entries such as J9145 (daratumumab), J9304 (pemetrexed) and others explicitly reference therapy policy 201936; check that policy for required step edits and documentation.
    ReferenceSummary / Instruction
    MA step therapy effective datesSeveral Medicare Advantage entries note new step therapy requirements effective 5/1/2026 (e.g., daratumumab J9145, Danyelza J9348); follow the MA effective dates when processing MA prior authorizations.
    MA cross-references to Part B Step Therapy Policy 201936Medicare Advantage criteria fields often instruct 'See Medicare Part B Step Therapy Policy 201936' — MA determinations should include compliance with that policy in addition to listed IC/LCD references.
    ReferenceSummary / Instruction
    Medicare Advantage entries referencing 201936Multiple MA entries (e.g., J9321 Epkinly, J9145 Darzalex, other oncology agents) reference Policy 201936 and note MA-specific step therapy requirements; include step therapy documentation for MA PA submissions.
    MA new step therapy requirements (various effective dates)Some MA entries indicate new MA step therapy requirements effective in 2026 (see individual drug lines for exact effective date and guidance).
    ReferenceSummary / Instruction
    Bevacizumab / Avastin family referencesBevacizumab products (Avastin biosimilars and branded bevacizumab entries) uniformly note: prior authorization required for non‑ophthalmic indications only; MA notes reference Medicare Part B Step Therapy Policy 201936.
    Other oncology agents referencing step therapyMultiple oncology agents listed alongside bevacizumab references (e.g., Q5107 Mvasi, Q5160 bevacizumab-nwgd) instruct providers to follow Part B Step Therapy Policy 201936 for applicable step edits and MA requirements.
    ReferenceSummary / Instruction
    Frequent 'See Medicare Part B Step Therapy Policy 201936'Many drug entries include the phrase 'See Medicare Part B Step Therapy Policy 201936' — treat that cross-reference as indicating step therapy applies per that policy for Medicare Advantage and as directed in the MA notes.
    Implication for PA submissionsWhen an entry references Policy 201936, submitters must include documentation demonstrating compliance with the Part B step therapy rules when requesting authorization for MA members or when the MA field references step therapy.
    ReferenceSummary / Instruction
    Multiple entries reference 201936Rituximab and several other biologics and oncology agents reference Medicare Part B Step Therapy Policy 201936 in their Medicare Advantage Criteria fields (e.g., rituximab-related entries, daratumumab, epcoritamab); follow policy 201936 for step therapy requirements.
    Provider action noteInclude relevant step therapy evidence or prior step trial documentation per Policy 201936 when submitting PAs for these agents under Medicare Advantage.
    ReferenceSummary / Instruction
    LCDs and Part B Step Therapy Policy 201936 applied to MASeveral entries pair LCD/LCD citations with 'See Medicare Part B Step Therapy Policy 201936' (examples include entries citing LCDs such as L38268/L35891); for MA claims, adjudication should follow both the LCD guidance and the Part B Step Therapy policy where indicated.
    Example guidanceEntries such as J9311 and immune globulin listings show LCD references plus instruction to see Policy 201936 — include LCD-required documentation and step therapy compliance documentation for MA PA reviews.
    ReferenceSummary / Instruction
    MA step therapy effective 5/1/2026 notedMultiple Medicare Advantage entries note new step therapy requirements effective 5/1/2026 (see J9145, J9348 and other oncology entries) — apply the MA effective date when determining step therapy applicability for MA members.
    Cross-reference to 201936These MA entries frequently cross‑reference Medicare Part B Step Therapy Policy 201936; providers must consult that policy for the step sequence and required prior trials or exceptions.
    ReferenceSummary / Instruction
    Multiple agents reference 201936Across the drug list many agents (oncology, biologics, colony stimulating factors, immune globulins) include 'See Medicare Part B Step Therapy Policy 201936' in MA fields — treat Policy 201936 as the controlling step therapy guidance when indicated.
    Practical note for reviewersWhen Policy 201936 is referenced, reviewers should verify prior-step treatments and any MA-specific effective dates (e.g., 5/1/2026) before approving or denying MA prior authorization requests.

    Definitions and Background

    Background summary: the plan defines investigational/experimental services as those lacking regulatory approval or robust evidence of outcomes comparable or superior to standard care. Medical Mutual aligns Medicare Advantage determinations with CMS guidance and limits Medicare coverage to clinically proven items and services; investigational services are considered non‑covered.

    Investigational / Experimental Services (definition field)
    DefinitionInvestigational/Experimental Services: services not approved by governing bodies or lacking evidence of comparable or superior outcomes to current practice standards.
    Coverage stanceSuch services are considered investigational and subject to non-coverage determinations per the plan definition.
    Source guidanceMedical Mutual aligns Medicare Advantage determinations with CMS guidance when assessing investigational services.
    Commercial Subject to Medication Sourcing Starting 1/1/2025 (definition/flag)
    DefinitionIndicates the payer will apply a medication sourcing requirement beginning January 1, 2025 for the listed drug (sometimes with sourcing types noted as A,C,S).
    ExampleJ1551/J1555 show 'Sourcing Starting 1/1/2025 = ✓ (A,C,S)'.
    Provider implicationSourcing requirement may change procurement or preferred supplier for affected drugs starting on 1/1/2025.
    Commercial Subject to Site of Care (definition/flag)
    DefinitionFlag that the drug is subject to site-of-care controls or specific site-of-care policy codes (e.g., 201317-MRx, IC-0581).
    ExampleSubcutaneous immune globulins (J1551, J1555) marked 'Commercial Subject to Site of Care = 201317-MRx ✓'.
    ActionVerify permitted administration site per the referenced policy when requesting prior authorization.
    Commercial Subject to Site of Care / Medication Sourcing (flags examples)
    Flag combinationExamples of entries that carry both Site of Care and Medication Sourcing flags; shown as ✓ with letter codes (A, C, S) where applicable.
    ExampleJ1551/J1555 include 'Commercial Subject to Site of Care = 201317-MRx ✓' and 'Sourcing Starting 1/1/2025 = ✓ (A,C,S)'.
    Provider requirementInclude both site-of-care and sourcing details in authorization submissions for items with both flags.
    Commercial Subject to Medication Sourcing Starting 1/1/2025 (flag)
    Operational flagMarks drugs that will be subject to medication sourcing beginning January 1, 2025; triggers sourcing workflows.
    ExampleNemluvio (J3590/C9399) shows a new PA effective 3/1/26 and sourcing start indicators in the table context; many entries list 1/1/2025 sourcing start.
    NoteSome entries also show later 'new medication sourcing' effective dates (4/1/26, 7/1/26) in addition to the 1/1/2025 start flag.
    Classification (therapeutic class labels)
    ClassificationTherapeutic classes such as Oncology, Rare disease, Immune globulin, Inflammatory conditions are annotated next to each drug code.
    PurposeClassifications guide which commercial criteria (IC codes) and Medicare policies apply to each drug entry.
    ExampleJ9309 (Polivy) listed as Oncology with sourcing and site-of-care annotations.
    Sourcing Starting (dates such as 1/1/2025)
    Definition'Sourcing Starting' indicates the date when the payer's sourcing/procurement requirement applies (commonly 1/1/2025).
    Other datesSome entries list additional effective dates for new sourcing requirements (e.g., 4/1/26, 7/1/26).
    ActionConfirm the specific sourcing start date on the drug line when planning authorization and procurement.
    Sourcing Starting (operational flag example)
    Operational exampleEntries show operational sourcing flags such as 'Commercial Subject = ✓ (A)' tied to the 'Sourcing Starting 1/1/2025' date.
    Example codesC9309 / J9207 display 'Sourcing Starting 1/1/2025 Commercial Subject = ✓ (A)' and note new PA/processing changes effective 1/1/26.
    Provider implicationApply sourcing workflows and new PA checks for codes with these operational flags on or after the effective date.
    Commercial Criteria / Medicare Advantage Criteria (IC numbers, LCD refs)
    Commercial Criteria examplesIC-series identifiers (e.g., IC-0718, IC-0679) and year-based codes (e.g., 201827) are listed beside drugs to indicate the applicable commercial criteria.
    Medicare Advantage cross-referencesMany entries reference Medicare Advantage LCDs/NCDs or 'See Medicare Part B Step Therapy Policy 201936' in addition to IC codes.
    Submission noteProviders should reference the listed IC/LCD/NCD identifiers in PA submissions to demonstrate compliance with required criteria.
    Self-administered (definition/example Tremfya)
    DefinitionSelf-administered: administered by the patient; such formulations may be 'not covered under Part B' and instead be covered under Part D (Article: A52527).
    ExampleTremfya (J1628) listed as self‑administered and 'not covered under Part B; may be covered under Part D'.
    Provider actionConfirm benefit applicability (medical vs pharmacy) and include route-of-administration documentation when requesting coverage.
    Medication sourcing (operational flag definition)
    DefinitionMedication sourcing: an operational flag indicating a new sourcing requirement for the drug starting on a specified effective date (examples include 'Sourcing Starting 1/1/2025' or later dates).
    Effect on processingTriggers sourcing-specific handling in prior authorization and procurement workflows for impacted drugs.
    ExamplesMultiple entries show sourcing flags (A,C,S) and effective dates for sourcing programs.
    Commercial Subject to Site of Care (definition/flag)
    DefinitionCommercial Subject to Site of Care: designation that a drug is subject to site-of-care commercial criteria (e.g., infusion center vs home) with an associated policy code and a ✓ flag.
    ExampleEntries such as J1551/J1555 (201317-MRx) and J9023 (IC-0295) indicate site-of-care controls apply.
    Provider implicationVerify the allowed administration site and include site-of-care information in PA submissions per the referenced criteria code.
    Policy Summary
    Payermedical mutual - ohio
    PolicyGlobal prior authorization for medical drugs (Global PA)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 3, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from Medical Drug Management for listed drugs before inpatient or outpatient administration.
    SourceLink
    On This Page
    Coverage Criteria and General PolicyCoding: HCPCS / CPT / J / Q CodesProvider Actions, Submission & Prior AuthorizationSite-of-Care and Medication SourcingInitial Therapy References & Criteria IdentifiersStep Therapy and Part B Step ProgramDefinitions and Background

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.